Skip navigation
Watchlist Sponsored By :

Current DateTime: 09:24:34 10 Jul 2009
LinksList Documentid: 24355697
  • Highest Grossing Movies

      What are the highest grossing movies of all time, adjusted for inflation? Click ahead to find out!

  • Most Expensive Places To Live

      Each year, Mercer Consulting assembles its ranking of the most expensive places to live. Mercer compiles information from 143 cities worldwide.

  • Recession-Resistant US Cities

      Some cities have been hit much harder than others during the recession. Here are the metro areas faring the best.


Current DateTime: 09:24:34 10 Jul 2009
LinksList Documentid: 24890560
  • Boom, Bust and Blame

      The inside story of the economic crisis that has gripped the entire world.

  • E3: Gaming's Cutting Edge

      North America's premier computer and video game trade show draws tens of thousands of professionals to experience the future of interactive entertainment.

  • The Fall of GM

      A look into the fall of General Motors as the automaker heads toward bankruptcy and an effective nationalization.

Bloodthinner Plavix Gets Big Boost in New  Study
By: Mike Huckman,, CNBC Pharmaceuticals Reporter | 05 Feb 2008 | 04:37 PM ET
Text Size

Heart patients with drug-coated stents who stop taking the popular bloodthinner Plavix are quickly put at a higher risk of death, according to a new study published in the "Journal of the American Medical Association."

The finding could boost sales of the blockbuster drug made by Bristol-Myers Squibb [BMY  Loading...      ()   ] and Sanofi-Aventis [SNY  Loading...      ()   ].

Drug-coated stents prop open clogged arteries, but some studies say that months or years later potentially fatal blood clots form.  Patients are put on Plavix to help prevent that.

Researchers who looked at the medical records of more than 3-thousand VA patients say within three months of going off the drug there was a significantly higher or nearly double the risk of death or having a heart attack.

Medical groups including the American Heart Association and the American College of Cardiology recently issued guidelines requiring drug-coated stent patients stay on Plavix for at least a year, maybe longer.

The JAMA study suggests those guidelines be revisited and that patients may need to stay on Plavix indefinitely, similar to people who take an aspirin a day to try to stave off a heart attack.

Plavix is among the top-selling drugs in the world.  One of the authors of the study has received funding from BMY and SNY.

© 2009 CNBC.com
Tools:
Print EmailAdd This share icon


Current DateTime: 08:26:52 10 Jul 2009
LinksList Documentid: 29778428

Current DateTime: 01:04:04 10 Jul 2009
LinksList Documentid: 29779196

Current DateTime: 07:29:15 10 Jul 2009
LinksList Documentid: 29779199

Current DateTime: 01:01:49 10 Jul 2009
LinksList Documentid: 29779198
CNBCCNBC
About CNBC  |  Site Map  |  Privacy Policy  |  Terms of Service  |  Video Reprints  |  Advertise  |  Help  |  Contact
Partners: AOL Money  |  BloggingStocks.com
CNBC is a Division of NBC Universal
  Data is a real-time snapshot *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
Thomson ReutersThomson Reuters